AETHLON MEDICAL INC 8-K

What Happened Aethlon Medical, Inc. (AEMD) filed an 8-K on June 4, 2026 reporting Amendment No. 1 to a prospectus supplement (originally filed Dec. 23, 2025) under its Form S-3 registration. The amendment updates the amount of common stock eligible for sale under the company's At Market Offering Agreement (ATM) with H.C. Wainwright & Co., LLC. Following the amendment, Aethlon may offer and sell additional Placement Shares having an aggregate offering price of up to $542,716. This amount is in addition to $1,849,457 of common stock previously sold under the prospectus supplement. The Registration Statement (File No. 333-292405) became effective Jan. 2, 2026. The legal opinion from Procopio, Cory, Hargreaves & Savitch, LLP relating to the Placement Shares was filed with the 8-K.

Key Details

• Amendment No. 1 filed June 4, 2026 to the prospectus supplement (original supplement filed Dec. 23, 2025).
• Up to $542,716 of additional common stock may be sold under the ATM; $1,849,457 was previously sold.
• As of June 1, 2026, Aethlon had 2,344,886 shares outstanding, with 2,337,629 shares held by non-affiliates (used to calculate public float under Form S-3).
• ATM placement agent: H.C. Wainwright & Co., LLC; other terms of the ATM remain unchanged.

Why It Matters This filing increases Aethlon’s capacity to raise capital incrementally through its existing ATM facility without a new offering registration. For investors, the update signals continued access to an on‑demand equity financing tool that can be used to fund operations or growth; however, the filing does not mean shares will be sold immediately or in full. The amounts involved are modest ($542.7K additional; $1.85M previously sold), so any dilution from future sales would likely be limited unless substantially more issuance occurs.